Key Highlights

● Iovance plunged on October 29 after releasing updated non-small cell lung cancer data.

● The data covered 69 patients, of whom 17 had an objective response.

● The company plans a supplemental Biologics License Application for lifileucel in 2027.

● Health care was the best-performing S&P 500 sector, making the drop a rare exception.

Iovance Biotherapeutics (NASDAQ:IOVA) shares plunged after the cell-therapy developer released updated results from its lung cancer program, bucking a strong day for health care stocks.

A sharp reaction to new data

Iovance Biotherapeutics plunged on Thursday, October 29, after releasing updated data from its program in non-small cell lung cancer. The stock was one of the steepest decliners in the Russell 2000, and among the biggest losers in the entire market.

Sources disagreed on the size of the drop. One report showed a steep decline, while another source's figures showed an even deeper fall by the close. Either way, Iovance lost a large slice of its Market Value in a single session.

The updated data covered 69 patients with non-squamous non-small cell lung cancer. Of those, 17 had an objective response to treatment, according to market data. An objective response generally means a tumour shrank by a defined amount.

What Iovance is developing

Iovance develops tumour-infiltrating lymphocyte therapies, a form of cell therapy that harvests immune cells from a patient's own tumour, expands them in a lab, and reinfuses them to attack the cancer. Its lead product, lifileucel, is already approved in advanced melanoma, and the company has been testing it in other solid tumours, including lung cancer.

The lung cancer data is important because the market for that disease is far larger than melanoma. Some investors may have hoped for a stronger response rate that would support a broader commercial opportunity.

The path forward

Iovance laid out its next steps alongside the data. Cohorts 1 and 2 of the study have completed enrollment, according to the reports. The company plans to file a supplemental Biologics License Application for lifileucel in 2027 and has also planned a new study.

Those plans suggest the company intends to keep pushing forward in lung cancer. But a filing that remains more than a year away leaves a long stretch before any potential approval, and investors reacted to the data available now.

A rare loser in a strong sector

The plunge stood out because health care was the best-performing sector in the S&P 500 on Thursday, according to market data. Eli Lilly (NYSE:LLY) rallied after reporting strong Revenue growth and raising guidance, and Merck (NYSE:MRK) climbed after beating forecasts and lifting its outlook. The pharmaceutical ETF IHE rose sharply at midday, according to media reports.

Smaller health care names also gained. Glaukos (NYSE:GKOS) and Teladoc (NYSE:TDOC) surged on strong results. Iovance was a notable exception, a reminder that biotech stocks often trade on clinical data rather than sector momentum.

The wider market

Small caps had a strong session overall. The Russell 2000 gained 28.71 points to close at 2,859.22, while the S&P 500 slipped 23.59 points to 7,720.39 and the Nasdaq Composite tumbled 365.13 points to 26,184.72. Alphabet (NASDAQ:GOOGL)'s worst day since its 2004 IPO dominated the large-cap headlines.

Investors rotated into health care, financials and real estate, according to market data. "Money is rotating within the market rather than leaving it," one market strategist said. That rotation did not extend to Iovance after its data update.

What to watch

Investors will look for further detail on the durability of the responses, safety results, and how the data compares with existing lung cancer treatments. Commentary at upcoming medical meetings or investor events could help clarify the outlook.

The timeline for the planned 2027 filing and the design of the new study will be key. Iovance's commercial performance with lifileucel in melanoma also matters, since that revenue funds ongoing development. Biotech sentiment broadly may hinge on rates, with the Fed's December 8–9 decision approaching.